Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease ...
WEB1 day ago · Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma ...
LP-184 Earns 3 FDA Rare Pediatric Disease Designations Across …
WEB10 hours ago · Lantern Pharma announces three U.S. FDA rare pediatric disease designations granted to LP-184 in multiple ultra rare children’s cancers. News Release. Lantern Pharma, Inc. September 23, 2024.
Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease ...
WEB1 day ago · Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. This brings the total number of RPDDs for LP-184 to 4, including one previously granted for ATRT (Atypical Teratoid Rhabdoid Tumors).
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation ...
WEB5 days ago · U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation and Rare Pediatric Disease designation for bexicaserin for the treatment of Dravet syndrome LA JOLLA, Calif., September ...
Lantern Pharma Says FDA Oks Rare Pediatric Disease Designations …
WEB1 day ago · Lantern's investigational drug candidate, LP-184, has shown preclinical activity in a wide range of solid tumors, garnering it multiple orphan and rare pediatric designations.
Somite Therapeutics Announces FDA Orphan Drug and Rare Pediatric ...
WEBSep 16, 2024 · News provided by. Somite Therapeutics Sep 16, 2024, 09:00 ET ... Rare Pediatric Disease Designation and Priority Review Voucher Program are granted for serious or life-threatening diseases that ...
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S
WEB4 days ago · MIPLYFFA was granted Breakthrough Therapy designation, Rare Pediatric Disease designation, Orphan Drug designation, and Fast Track designation by the FDA for the treatment of NPC.
LP-184 Earns 3 FDA Rare Pediatric Disease Designations in Solid …
WEB2 hours ago · LP-184 has earned 3 RPDDs in ultra-rare tumors including rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma. 1. The FDA defines rare pediatric diseases as serious or life-threatening conditions primarily affecting patients under the age of 18 with fewer than 200,000 incidences in the US. LP-184 …
FDA Approves New Drug to Treat Niemann-Pick Disease, Type C
WEB23 hours ago · Today’s action further underscores the agency’s commitment to support development of new treatments for rare diseases,” said Janet Maynard, M.D., M.H.S., director of the Office of Rare ...
Rare Pediatric Disease (RPD) Designation and Voucher Programs
WEBUnder Section 529 to the Federal Food, Drug, and Cosmetic Act (FD&C Act), FDA will award priority review vouchers to sponsors of rare pediatric disease product applications that meet certain...
Skip to content